While PDLIM2 is epigenetically repressed in more than 75% of all human lung cancer cases and PDLIM2 repression is associated with poor prognosis, global or lung epithelial-specific deletion of PDLIM2 in mice leads to increased lung cancer development and chemoresistance, and remarkably, complete anti-PD-1 resistance. This evidence concerns the gene PDLIM2 and lung carcinoma.